

Intrinseque Health secures ISO/IEC 27001:2022 certification

24 September 2025 | News

Reinforcing global leadership in quality and data security



Intrinseque Health has earned the ISO/IEC 27001:2022 certification, a globally recognised standard for information security management. This new achievement further strengthens the company's already impressive portfolio of certifications, which includes EN ISO 13485, ISO 9001, and GDPMDS, reinforcing its position as a trusted partner for clinical trial support services worldwide.

Known for its operational excellence and commitment to quality, Intrinseque Health has consistently delivered top-tier clinical supply chain solutions to pharmaceutical, biotechnology, and contract research organisations.

The addition of the ISO/IEC 27001:2022 certification marks a pivotal moment, ensuring that the company's systems uphold not only high standards of quality and compliance but also safeguard sensitive information with the highest levels of security.

"Information security is no longer optional; it is an essential expectation from our clients and partners," said Nitin Jain, President & CEO, Intrinseque Health. "Achieving ISO/IEC 27001:2022 certification demonstrates our proactive commitment to protecting our information assets. This reinforces the trust placed in us by global stakeholders and ensures that we continue to meet and exceed the international standards for both quality and security."

The certification process included a thorough independent audit, which assessed Intrinseque Health's governance structure, risk management processes, and security systems. The successful outcome confirms that the company has developed an integrated approach that not only prevents data breaches and reduces risks but also ensures business continuity and resilience in an ever-changing regulatory landscape.

As the clinical research industry faces increasingly complex challenges, from regulatory compliance to data protection, Intrinseque Health's attainment of ISO/IEC 27001:2022 certification represents a key milestone that enhances its ability to support global clinical trials with confidence and credibility.

Around the globe, Intrinseque Health has offices in countries like the United States (Delaware), The Netherlands (Amsterdam), United Kingdom (London), China (Beijing), Taiwan (Taipei) & Korea (Seoul), India (Delhi), Malaysia (Melaka) and Singapore.